Published in Vasc Health Risk Manag on January 20, 2014
Management of Myocardial Injury After Noncardiac Surgery Trial (MANAGE) | NCT01661101
Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med (2012) 5.56
Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med (2011) 4.81
Newly identified events in the RE-LY trial. N Engl J Med (2010) 3.35
Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors. Am J Cardiol (2013) 2.19
Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation (2012) 2.18
Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation (2012) 1.83
Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial. JAMA (2013) 1.45
Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients? Am J Med (2010) 1.24
Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction? J Thromb Thrombolysis (2013) 0.89
Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. J Am Coll Cardiol (2013) 0.88
Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials. BMJ Open (2012) 0.87
Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment. Vasc Health Risk Manag (2013) 0.82
Bivalirudin in acute coronary syndromes and percutaneous coronary intervention: should we use it? Heart Lung Circ (2013) 0.80